KIT and gastrointestinal stromal tumor: We first analyzed LIX1 expression in imatinib/sunitinib-sensitive (GIST-T1) and imatinib-resistant (GIST-T1/670) GIST cell lines upon blockade of KIT signaling using TKIs.